Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Authors
Stefan AnkerJanet SchneeMilton Packer
Journal
New England Journal of Medicine
Published
August 27, 2021

Abstract

Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1056/nejmoa2107038

License

Unknown License
Empagliflozin in Heart Failure with a Preserved Ejection Fraction